Maze Therapeutics (NASDAQ:MAZE) Announces Earnings Results, Misses Expectations By $10.72 EPS

Maze Therapeutics (NASDAQ:MAZE) posted its earnings results on Monday. The company reported ($18.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($7.60) by ($10.72), Zacks reports.

Maze Therapeutics Stock Performance

MAZE stock opened at $11.42 on Monday. Maze Therapeutics has a one year low of $9.88 and a one year high of $17.00.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on MAZE shares. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Guggenheim started coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They issued a “buy” rating and a $19.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an “overweight” rating and a $30.00 price target on the stock. Leerink Partners started coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $28.00 price objective for the company. Finally, Leerink Partnrs upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 25th. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $25.67.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.